Literature DB >> 10469210

Atypical lobular hyperplasia and lobular carcinoma in situ: surgical and molecular pathology.

S C Lishman1, S R Lakhani.   

Abstract

Lobular carcinoma in situ and atypical lobular hyperplasia were first described over 50 years ago. Despite this long incubation period, the biological nature of the lesions remains controversial. They are generally regarded as 'risk indicators' of invasive cancer rather than true precursor lesions. When first described, the 'carcinoma in situ' designation implied radical treatment in the form of a mastectomy. Subsequent observation has shown that the lesions are often multifocal and bilateral. The risk to the woman of developing invasive cancer after a diagnosis of lobular carcinoma in situ is small. Hence, the lesion has increasingly been regarded as a 'hyperplastic' proliferation, which although predicting for subsequent risk of invasive cancer, does not in itself need treatment. In this review, we challenge this view and explore the developments in the understanding of this controversial entity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469210     DOI: 10.1046/j.1365-2559.1999.00815.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  [Concepts and problems of lobular neoplasia].

Authors:  H P Sinn; B Helmchen; S Aulmann
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

2.  Does histopathological examination of breast reduction specimens affect patient management and clinical follow up?

Authors:  I S Cook; C E Fuller
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

3.  E-cadherin expression: a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies.

Authors:  Kanthilatha Pai; Poornima Baliga; Bishwo Lal Shrestha
Journal:  J Clin Diagn Res       Date:  2013-03-18

Review 4.  Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.

Authors:  Flora Zagouri; Theodoros N Sergentanis; George C Zografos
Journal:  World J Surg Oncol       Date:  2007-05-31       Impact factor: 2.754

Review 5.  The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions.

Authors:  Jorge S Reis-Filho; Sunil R Lakhani
Journal:  Breast Cancer Res       Date:  2003-10-09       Impact factor: 6.466

6.  Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.

Authors:  E A Rakha; D Soria; A R Green; C Lemetre; D G Powe; C C Nolan; J M Garibaldi; G Ball; I O Ellis
Journal:  Br J Cancer       Date:  2014-03-11       Impact factor: 7.640

7.  Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9.

Authors:  Dengfeng Cao; Kornelia Polyak; Marc K Halushka; Hind Nassar; Nina Kouprina; Christine Iacobuzio-Donahue; Xinyan Wu; Saraswati Sukumar; Jessica Hicks; Angelo De Marzo; Pedram Argani
Journal:  Breast Cancer Res       Date:  2008-10-27       Impact factor: 6.466

8.  Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening.

Authors:  R Rawal; J Lorenzo Bermejo; K Hemminki
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.